OXUR.BR Stock - Oxurion N.V.
Unlock GoAI Insights for OXUR.BR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3,000 | $263,000 | $595,000 | $1.13M | $2.08M |
| Gross Profit | $-40,000 | $104,000 | $-271,000 | $-161,000 | $419,000 |
| Gross Margin | -1333.3% | 39.5% | -45.5% | -14.3% | 20.2% |
| Operating Income | $382,000 | $-12,110,000 | $-22,946,000 | $-28,688,000 | $-29,755,000 |
| Net Income | $119,000 | $-18,969,000 | $-31,685,000 | $-29,158,000 | $-28,012,000 |
| Net Margin | 3966.7% | -7212.5% | -5325.2% | -2584.9% | -1348.0% |
| EPS | $0.09 | $-114.80 | $-3726.80 | $-7591.10 | $-7315.40 |
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
Visit WebsiteEarnings History & Surprises
OXUR.BREPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 3, 2026 | — | — | — | — |
Q3 2025 | Sep 30, 2025 | — | $-0.14 | — | — |
Q2 2025 | Apr 11, 2025 | — | $2.56 | — | — |
Q3 2024 | Sep 30, 2024 | — | $-2.47 | — | — |
Q2 2024 | Apr 15, 2024 | — | $-23.92 | — | — |
Q3 2023 | Sep 29, 2023 | — | $-200.00 | — | — |
Q1 2023 | Mar 24, 2023 | $-3600.00 | $-526.78 | +85.4% | ✓ BEAT |
Q2 2022 | Jun 30, 2022 | $-3900.00 | $-3200.00 | +17.9% | ✓ BEAT |
Q4 2021 | Dec 31, 2021 | $-4200.00 | $-3449.81 | +17.9% | ✓ BEAT |
Q3 2021 | Sep 9, 2021 | $-0.36 | $-4141.34 | -1150272.3% | ✗ MISS |
Q1 2021 | Mar 18, 2021 | $-5200.00 | $-3884.11 | +25.3% | ✓ BEAT |
Q4 2020 | Oct 16, 2020 | $-4100.00 | $-3431.27 | +16.3% | ✓ BEAT |
Q2 2020 | May 7, 2020 | $-0.45 | $-4833.91 | -1074103.2% | ✗ MISS |
Q4 2019 | Oct 18, 2019 | — | $-8700.78 | — | — |
Q1 2019 | Mar 8, 2019 | — | $-6122.96 | — | — |
Q3 2018 | Sep 6, 2018 | — | $-3926.67 | — | — |
Q1 2018 | Mar 16, 2018 | — | $10400.00 | — | — |
Q4 2017 | Oct 20, 2017 | — | $-4215.06 | — | — |
Q2 2017 | Jun 1, 2017 | — | $-12549.89 | — | — |
Q3 2016 | Aug 25, 2016 | — | $-4160.21 | — | — |
Latest News
Frequently Asked Questions about OXUR.BR
What is OXUR.BR's current stock price?
What is the analyst price target for OXUR.BR?
What sector is Oxurion N.V. in?
What is OXUR.BR's market cap?
Does OXUR.BR pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to OXUR.BR for comparison